A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

Recruiting now · Phase 1

Conditions studied: Healthy Volunteer

In brief

The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.

Key facts

Study ID

NCT07466550

Run by

AbbVie

People needed

60

Starts

2026-06-04

Expected to finish

2027-01-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body weight between 40 kg and 100 kg inclusive at screening and upon initial confinement.
• BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

You may not qualify if…

• Exposure to any anti-interleukin-12/23 or anti interleukin-23 treatment for at least one year prior to Screening.
• Intention to perform strenuous exercise to which the subject is unaccustomed within one week prior to administration of first dose of study treatment or during the study.

Where it is running

• CenExel ACT- Anaheim Clinical Trials /ID# 281821 — Anaheim, California, United States (enrolling)
• Cpmi /Id# 281783 — Miami, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.